Header

UZH-Logo

Maintenance Infos

Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation


Robinson, Cécile A; Inci, Ilhan; Naegeli, Mirjam; Murer, Christian; Schuurmans, Macé M; Urosevic-Maiwald, Mirjana; Schüpbach, Reto; Weder, Walter; Benden, Christian (2018). Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation. Pediatric Transplantation, 22(3):e13145.

Abstract

ECP is an established "second-line" treatment for CLAD/BOS. Recently, ECP was used for the first time in an adolescent CF patient as a "second-line" treatment therapy in life-threatening primary graft dysfunction following lung transplantation who deteriorated despite extensive treatment including ECMO and ATG. Within 10 days after initiation of ECP twice weekly, allograft function and clinical status improved significantly and the patient was weaned from mechanical ventilation support. ECP has been continued every 2 weeks since. Two hundred days after lung transplantation, the patient has an acceptable allograft function (FEV1 67%) and no signs of allograft rejection. We advocate that use of ECP and its immunomodulatory effects should be evaluated in the early period following lung transplantation.
KEYWORDS: extracorporeal photopheresis; lung transplantation; primary graft dysfunction

Abstract

ECP is an established "second-line" treatment for CLAD/BOS. Recently, ECP was used for the first time in an adolescent CF patient as a "second-line" treatment therapy in life-threatening primary graft dysfunction following lung transplantation who deteriorated despite extensive treatment including ECMO and ATG. Within 10 days after initiation of ECP twice weekly, allograft function and clinical status improved significantly and the patient was weaned from mechanical ventilation support. ECP has been continued every 2 weeks since. Two hundred days after lung transplantation, the patient has an acceptable allograft function (FEV1 67%) and no signs of allograft rejection. We advocate that use of ECP and its immunomodulatory effects should be evaluated in the early period following lung transplantation.
KEYWORDS: extracorporeal photopheresis; lung transplantation; primary graft dysfunction

Statistics

Citations

Altmetrics

Additional indexing

Item Type:Journal Article, not_refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Pneumology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Thoracic Surgery
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 May 2018
Deposited On:04 Jan 2019 09:45
Last Modified:25 Jan 2019 15:19
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:1397-3142
OA Status:Closed
Publisher DOI:https://doi.org/10.1111/petr.13145
PubMed ID:29380491

Download

Full text not available from this repository.
View at publisher

Get full-text in a library